Our focus is deeply rooted
in fibrotic lung disease

Financial reports

Year-end report 2020 Interim report, Q3 Interim report, Q2 Interim report, Q1 Read more

Latest press releases

2021-02-26 Increase of number of shares and votes in Vicore Pharma
2021-02-26 Year-end report 2020
Read more Subscribe

Upcoming events

2021-03-09 - 2021-03-11

Carnegie Nordic Virtual Healthcare seminar

2021-04-21

Nordic Life Science Days, Malmö

Read more

Latest news

See all

C21 shows promise against COVID-19 where other drugs have failed

By Carl-Johan Dalsgaard, CEO of Vicore Pharma The rapid development, and now distribution,… Read More

Top line data on the ATTRACT study

It’s been a very busy few months at Vicore as we’ve continued to… Read More

About us

Vicore Pharma is a rare disease pharmaceutical company focused on rare lung disorders and related indications. The company currently has two drug development programs, VP01, VP02 and VP03.

The VP01 project aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis (IPF), systemic sclerosis and COVID-19. The VP02 project is based on a new formulation and delivery route of an existing immunomodulatory compound (an “IMiD”). The VP02 project focuses on the underlying disease and the severe cough associated with IPF. Both projects are also being actively evaluated for other indications within the field of interstitial lung diseases which have a significant unmet need. The VP03 project includes follow-up molecules for C21.

The company’s shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see www.vicorepharma.com.

Fibrotic lung disease

Idiopathic pulmonary fibrosis (IPF) is the most common type of pulmonary fibrosis and is a severe and devastating disease with no known cause. It is characterized by a shrinking of the lungs due to the irreversible formation of fibrosis (i.e. scar tissue) causing stiffness, an irreversible loss of lung function and difficulty in breathing.

Our Vision

Vicore’s vision is to remove the pain and suffering caused by fibrotic lung disease. As a company, we pride ourselves on our collaborative approach to science and are committed to working closely with the patient community, scientific experts and clinicians to find innovative solutions that meet their needs.